Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen

Prostate

Volumn 40, Issue 2, 1999, Pages 76-82

  Henriksson, Peter ^a   Carlström, Kjell ^a   Pousette, Åke ^a   Gunnarsson, P O ^b   Johansson, C J ^b   Eriksson, Birgitta ^b   Altersgård Brorsson, Ann Kristin ^b   Nordle, Örjan ^b   Stege, Reinhard ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Pharmacia & Upjohn AB   (Sweden)

Author keywords

Adverse effects; Estrogens; Parenteral administration; Pharmacokinetics; Prostatic neoplasms; Testosterone

Indexed keywords

BLOOD CLOTTING FACTOR 7; POLYESTRADIOL PHOSPHATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CALCULATION; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; FOLLOW UP; HUMAN; MALE; MORBIDITY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; ESTRADIOL; FACTOR VII; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 0032974259     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990701)40:2<76::AID-PROS2>3.0.CO;2-Q     Document Type: Article

References (30)

1. Veterans Administration Cooperative Urological Research Group. Carcinoma of the prostate: treatment comparisons. J Urol 1967;98:516-522.
2. Veterans Administration Cooperative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011-1017.
3. Henriksson P, Edhag O. Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects. Br Med J [Clin Res] 1986; 293:413-415.
4. Henriksson P, Johansson S-E. Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen. Am J Epidemiol 1987;125:970-978.
5. Henriksson P, Blombäck M, Bratt G, Edhag O, Eriksson A. Activators and inhibitors of coagulation and fibrinolysis in patients with prostatic cancer treated with estrogen or orchidectomy. Thromb Res 1986;44:783-791.
6. Daehlin L, Damber JE, von Schoultz B, Bergman B. The oestrogenic effects of ethinyl oestradiol/polyestradiol phosphate and estramustine phosphate in patients with prostatic carcinoma. Br J Urol 1986;58:412-416.
7. Damber MG, Sandström B, von Schoultz B, Stigbrand T. A new and sensitive method for quantifying and comparing the biological potency of various estrogens in man. Acta Obstet Gynecol Scand 1979;58:527-530.
8. Goebelsmann MD, Mashchak CA, Mishell DR. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol 1985;151:868-877.
9. Henriksson P, Blombäck M, Bratt G, Edhag O, Eriksson A, Vesterqvist O. Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer. Med Oncol Tumor Pharmacother 1989;6:219-225.
10. Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y, Thompson SG. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980;i:1050-1054.
11. Henriksson P, Blombäck M, Eriksson A, Stege R, Carlström K. Effects of parenteral estrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 1990;65:282-285.
12. Henriksson P, Eriksson A, Stege R, Collste L, Pousette Å, von Schoultz B, Carlström K. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate 1988;13:257-261.
13. Carlström K, Collste L, Eriksson A, Henriksson P, Pousette Å, Stege R, von Schoultz B. A comparison of androgen status in patients with prostatic cancer, treated with oral or parenteral estrogens or by orchidectomy. Prostate 1989;14:177-182.
14. Stege R, Gunnarsson PO, Johansson C-J, Olsson P, Pousette Å, Carlström K. Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin®) in prostatic cancer patients. Prostate 1996;28:307-310.
15. Stege R, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A. Single drug polyestradiol phosphate therapy in prostatic cancer. Am J Clin Oncol [Suppl] 1988;11:101-103.
16. Statistical Consultants, Inc. PCNONLIN and NONLIN84: software for the statistical analysis of nonlinear models. Am Stat 1986;40:52.
17. Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH, Wagner G. UICC TNM Atlas, 7th ed. Berlin Heidelberg New York: Springer Verlag; 1989. 220-226.
18. Franzén S, Giertz G, Zaijcek J. Cytological diagnosis of prostatic tumors by transrectal aspiration biopsy: a preliminary report. J Urol 1960;32:193-196.
19. Esposti PL. Cytological malignancy grading of prostatic carcinoma by transrectal aspiration biopsy; a five-year follow-up of 469 hormone treated patients. Scand J Urol Nephrol 1971;5:199-202.
20. Seligsohn U, Österrud B, Rapaport SI. Coupled amidolytic assay for factor VII. Its use with clotting assay to determine the activity state of factor VII. Blood 1978,52:978-988.
21. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
22. Huggins C, Stevens RE Jr, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209-223.
23. Stege R, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette Å, von Schoultz B. Single-drug parenteral estrogen treatment in prostatic cancer: a study of two maintenance-dose regimens. Prostate 1989;14:183-188.
24. Henriksson P, Stege R. Cost comparison of parenteral estrogen and conventional hormonal treatment in patients with prostatic cancer. Int J Technol Assessm Health Care 1991;7:220-225.
25. Carlström K, Stege R, Henriksson P, Grande M, Gunnarsson PO, Pousette Å. Possible bone preserving capacity of high dose intramuscular depot estrogen as compared to orchidectomy in patients with prostatic carcinoma. Prostate 1997;31:193-197.
26. Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp(a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest 1992;89:1166-1177.
27. Berglund L, Carlström L, Stege R, Gottlieb C, Eriksson M, Angelin B, Henriksson P. Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males with prostatic carcinoma. J Clin Endocrinol Metabol 1996;81:2633-2637.
28. Eriksson M, Berglund L, Rudling M, Henriksson P, Angelin B. Effects of estrogen on low density lipoprotein metabolism in males. Short-term and long-term studies during hormonal treatment of prostatic carcinoma. J Clin Invest 1989;84:802-810.
29. Wallentin L, Varenhorst E. Changes of plasma lipid metabolism in males during estrogen treatment for prostatic carcinoma. J Clin Endocrinol Metab 1978;47:596-599.
30. Henriksson P, Einarsson K, Eriksson A, Kelter U, Angelin B. Estrogen-induced gallstone formation in males: relation to changes in serum and biliary lipids during hormonal treatment of prostatic carcinoma. J Clin Invest 1989;84:811-816.